Emerging Drug Could Help Treat a Common Liver Disease

Newswise — Stony Brook, NY, December 20, 2017 – Treating a liver disease called NASH (non-alcoholic steatohepatitis), which affects 10 to 15 percent of obese individuals with type-2 diabetes worldwide, is difficult. But now scientists believe they have found a pharmacologic approach that may inhibit NASH, and thus stop deadly conditions that result from NASH such as cirrhosis and liver cancer.

Tadashi Honda, PhD, Research Professor in the Department of Chemistry, and Director of the Anti-Inflammatory Research Laboratory in the ICB & DD, along with colleagues at the Universities of Dundee and St. Andrews, are testing a drug invented by Dr. Honda called TBE-31. They found that TBE-31 activates a protein called Nrf2 in mice that neutralizes a group of damaging oxidizing materials in the liver called reactive oxygen species (ROS). The drug switches off ROS buildup in NASH, and therefore stops the condition and prevents liver damage. Their findings are published in latest edition of Cellular and Molecular Gastroenterology and Hepatology.

Currently there is no known drug that treats NASH. Individuals with NASH can only reduce morbidity and complications from the disease by making lifestyle changes.


About Stony Brook University    Stony Brook University is going beyond the expectations of what today’s public universities can accomplish. Since its founding in 1957, this young university has grown to become a flagship as one of only four University Center campuses in the State University of New York (SUNY) system with more than 26,000 students and 2,600 faculty members, and 18 NCAA Division I athletic programs. Our faculty have earned numerous prestigious awards, including the Nobel Prize, Pulitzer Prize, Indianapolis Prize for animal conservation, Abel Prize and the inaugural Breakthrough Prize in Mathematics. The University offers students an elite education with an outstanding return on investment: U.S. News & World Report ranks Stony Brook among the top 50 public universities in the nation. Its membership in the Association of American Universities (AAU) places Stony Brook among the top 62 research institutions in North America. As part of the management team of Brookhaven National Laboratory, the University joins a prestigious group of universities that have a role in running federal R&D labs. Stony Brook University is a driving force in the region’s economy, generating nearly 60,000 jobs and an annual economic impact of more than $4.6 billion. Our state, country and world demand ambitious ideas, imaginative solutions and exceptional leadership to forge a better future for all. The students, alumni, researchers and faculty of Stony Brook University are prepared to meet this challenge.

Register for reporter access to contact details

Cellular and Molecular Gastroenterology and Hepatology